6dzm
From Proteopedia
(Difference between revisions)
Line 3: | Line 3: | ||
<StructureSection load='6dzm' size='340' side='right' caption='[[6dzm]], [[Resolution|resolution]] 4.29Å' scene=''> | <StructureSection load='6dzm' size='340' side='right' caption='[[6dzm]], [[Resolution|resolution]] 4.29Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
- | <table><tr><td colspan='2'>[[6dzm]] is a 12 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6DZM OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6DZM FirstGlance]. <br> | + | <table><tr><td colspan='2'>[[6dzm]] is a 12 chain structure with sequence from [http://en.wikipedia.org/wiki/Bdbv Bdbv] and [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6DZM OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6DZM FirstGlance]. <br> |
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=BMA:BETA-D-MANNOSE'>BMA</scene>, <scene name='pdbligand=MAN:ALPHA-D-MANNOSE'>MAN</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr> | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=BMA:BETA-D-MANNOSE'>BMA</scene>, <scene name='pdbligand=MAN:ALPHA-D-MANNOSE'>MAN</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr> | ||
+ | <tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">GP, DF49_53413gpGP, DH33_45404gpGP ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=565995 BDBV])</td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6dzm FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6dzm OCA], [http://pdbe.org/6dzm PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6dzm RCSB], [http://www.ebi.ac.uk/pdbsum/6dzm PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6dzm ProSAT]</span></td></tr> | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6dzm FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6dzm OCA], [http://pdbe.org/6dzm PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6dzm RCSB], [http://www.ebi.ac.uk/pdbsum/6dzm PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6dzm ProSAT]</span></td></tr> | ||
</table> | </table> | ||
+ | <div style="background-color:#fffaf0;"> | ||
+ | == Publication Abstract from PubMed == | ||
+ | Monoclonal antibodies (mAbs) with pan-ebolavirus cross-reactivity are highly desirable, but development of such mAbs is limited by a lack of a molecular understanding of cross-reactive epitopes. The antibody ADI-15878 was previously identified from a human survivor of Ebola virus Makona variant (EBOV/Mak) infection. This mAb demonstrated potent neutralizing activity against all known ebolaviruses and provided protection in rodent and ferret models against three ebolavirus species. Here, we describe the unliganded crystal structure of ADI-15878 as well as the cryo-EM structures of ADI-15878 in complex with the EBOV/Mak and Bundibugyo virus (BDBV) glycoproteins (GPs). ADI-15878 binds through an induced-fit mechanism by targeting highly conserved residues in the internal fusion loop (IFL), bridging across GP protomers via the heptad repeat 1 (HR1) region. Our structures provide a more complete description of the ebolavirus immunogenic landscape, as well as a molecular basis for how rare but potent antibodies target conserved filoviral fusion machinery. | ||
+ | |||
+ | Structural Basis of Pan-Ebolavirus Neutralization by an Antibody Targeting the Glycoprotein Fusion Loop.,Murin CD, Bruhn JF, Bornholdt ZA, Copps J, Stanfield R, Ward AB Cell Rep. 2018 Sep 4;24(10):2723-2732.e4. doi: 10.1016/j.celrep.2018.08.009. PMID:30184505<ref>PMID:30184505</ref> | ||
+ | |||
+ | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | ||
+ | </div> | ||
+ | <div class="pdbe-citations 6dzm" style="background-color:#fffaf0;"></div> | ||
+ | == References == | ||
+ | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
+ | [[Category: Bdbv]] | ||
+ | [[Category: Human]] | ||
[[Category: Murin, C D]] | [[Category: Murin, C D]] | ||
[[Category: Ward, A B]] | [[Category: Ward, A B]] |
Revision as of 20:21, 19 September 2018
Bundibugyo virus GP (mucin-deleted) in complex with pan-ebolavirus human antibody ADI-15878 Fab
|
Categories: Bdbv | Human | Murin, C D | Ward, A B | Antibody | Glycoprotein | Hr1 | Internal fusion loop | Pan-ebolavirus | Viral protein